AnaptysBio Stock Forecast, Price & News

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

Is AnaptysBio a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AnaptysBio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View analyst ratings for AnaptysBio or view top-rated stocks.

How has AnaptysBio's stock price been impacted by Coronavirus?

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANAB stock has increased by 104.1% and is now trading at $31.09.
View which stocks have been most impacted by COVID-19.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for AnaptysBio.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.85) by $0.61. AnaptysBio had a trailing twelve-month return on equity of 2.17% and a net margin of 6.87%.
View AnaptysBio's earnings history.

What price target have analysts set for ANAB?

6 Wall Street analysts have issued twelve-month target prices for AnaptysBio's shares. Their forecasts range from $29.00 to $44.00. On average, they expect AnaptysBio's share price to reach $35.50 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts' price targets for AnaptysBio or view top-rated stocks among Wall Street analysts.

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:

• Hamza Suria, President, Chief Executive Officer & Director
• Eric J. Loumeau, Chief Operating Officer & General Counsel (LinkedIn Profile)
• Dennis M. Mulroy, Chief Financial Officer
• Paul F. Lizzul, Chief Medical Officer
• David McKeon, Vice President & Controller

Who are some of AnaptysBio's key competitors?

Some companies that are related to AnaptysBio include Intra-Cellular Therapies (ITCI), Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Insmed (INSM), Cytokinetics (CYTK), Arcus Biosciences (RCUS), Galapagos (GLPG), Hypera (HYPMY), Cryoport (CYRX), ACADIA Pharmaceuticals (ACAD), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH) and OPKO Health (OPK).
View all of ANAB's competitors.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.82%), Dimensional Fund Advisors LP (2.75%), Great Point Partners LLC (2.00%), Rock Springs Capital Management LP (1.95%), Geode Capital Management LLC (1.30%) and Goldman Sachs Group Inc. (1.26%). Company insiders that own AnaptysBio stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends for AnaptysBio.

Which major investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, Two Sigma Advisers LP, Morgan Stanley, Two Sigma Investments LP, Citigroup Inc., Geode Capital Management LLC, and Rafferty Asset Management LLC. Company insiders that have sold AnaptysBio company stock in the last year include Eric J Loumeau, and Hamza Suria.
View insider buying and selling activity for AnaptysBio or view top insider-selling stocks.

Which major investors are buying AnaptysBio stock?

ANAB stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Eversept Partners LP, Goldman Sachs Group Inc., Fisher Asset Management LLC, Ensign Peak Advisors Inc, Ziegler Capital Management LLC, Panagora Asset Management Inc., and Millennium Management LLC.
View insider buying and selling activity for AnaptysBio or or view top insider-buying stocks.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $31.09.

How much money does AnaptysBio make?

AnaptysBio has a market capitalization of $855.22 million and generates $75 million in revenue each year. The biotechnology company earns $-19.93 million in net income (profit) each year or $0.28 on an earnings per share basis.

How many employees does AnaptysBio have?

AnaptysBio employs 94 workers across the globe.

What is AnaptysBio's official website?

The official website for AnaptysBio is www.anaptysbio.com.

Where are AnaptysBio's headquarters?

AnaptysBio is headquartered at 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 362-6295 or via email at [email protected].